82 FR 60200 - Proposed Information Collection Activity; Comment Request
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Administration for Children and Families Federal Register Volume 82, Issue 242 (December 19, 2017)
Administration for Children and Families
Federal Register Volume 82, Issue 242 (December 19, 2017)
| Page Range | 60200-60201 | |
| FR Document | 2017-27306 |
[Federal Register Volume 82, Number 242 (Tuesday, December 19, 2017)] [Notices] [Pages 60200-60201] From the Federal Register Online [www.thefederalregister.org] [FR Doc No: 2017-27306] ----------------------------------------------------------------------- DEPARTMENT OF HEALTH AND HUMAN SERVICES Administration for Children and Families Proposed Information Collection Activity; Comment Request Proposed Projects Title: ACF Generic Clearance for Mandatory Grant Financial Reports. OMB No.: 0970--New. Description: OMB has granted permission for ACF to submit a request for a generic clearance to be used for the financial reports used in the administration of mandatory grants. This clearance supports the Departments initiative of Generating Efficiencies through Streamlined Processes by employing an abbreviated process. If approved program offices will be at liberty to tailor a financial report to their specific needs rather than adhering to a standard form. Respondents: States and Territories. Annual Burden Estimates ---------------------------------------------------------------------------------------------------------------- Number of Average burden Instrument Number of responses per hours per Total burden respondents respondent response hours ---------------------------------------------------------------------------------------------------------------- Mandatory Grant Financial Reports........... 900 4 5 18,000 ---------------------------------------------------------------------------------------------------------------- Estimated Total Annual Burden Hours: In compliance with the requirements of the Paperwork Reduction Act of 1995 (Pub. L. 104-13, 44 U.S.C. Chap. 35), the Administration for Children and Families is soliciting public comment on the specific aspects of the information collection described above. Copies of the proposed collection of information can be obtained and comments may be forwarded by writing to the Administration for Children and Families, Office of Planning, Research and Evaluation, 330 C Street SW, Washington, DC 20201. Attn: ACF Reports Clearance Officer. Email address: [email protected]. All requests should be identified by the title of the information collection. The Department specifically requests comments on: (a) Whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information shall have practical utility; (b) the accuracy of the agency's estimate of the burden of the proposed collection of information; (c) the quality, utility, and clarity of the information to be collected; and (d) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques or other forms of information technology. Consideration will be given to [[Page 60201]] comments and suggestions submitted within 60 days of this publication. Robert Sargis, Reports Clearance Officer. [FR Doc. 2017-27306 Filed 12-18-17; 8:45 am] BILLING CODE 4184-01-P
![60200 Federal Register / Vol. 82, No. 242 / Tuesday, December 19, 2017 / Notices
age and older through educating and and how program effectiveness may responders, social service providers,
training first responders and other key vary among different sub-populations laypersons including end users and
community sectors on the prevention of and settings, and to increase knowledge their family and friend. All focus groups
prescription drug/opioid overdose- of barriers and facilitators to program and interviews will be analyzed through
related deaths, including the purchase implementation. qualitative content analysis, including
and distribution of naloxone. SAMHSA Researchers will use key informant utilization of a systematic coding
is funding the grant and CDC is interviews and focus groups with scheme.
responsible for conducting the grantee participants in the activities enacted by Total burden in hours for this
evaluation. the twelve state grant recipients. collection is 381. There are no costs to
The intended use of the resulting data Participants will include state respondents other than their time. CDC
is to increase CDC and SAMHSA administrators of the grant and other requests a three-year OMB approval to
understanding of the scope and impact PDO/Naloxone stakeholders including collect the necessary project-related
of the program on overdose fatalities advisory council members, first information.
ESTIMATED ANNUALIZED BURDEN HOURS
Average
Number of
Number of burden per
Type of respondents Form name responses per
respondents response
respondent (in hours)
PDO/Naloxone Advisory Committee Members Focus Group Discussion Guide ..................... 140 1 1.5
and Grantees.
PDO/Naloxone Grantees ................................ Key Informant Interview Guide for Grantees 36 1 1
PDO/Naloxone Stakeholders and Partners .... Key Informant Interview Guide for Partners .. 84 1 1
PDO/Naloxone Laypersons ............................ Key Informant Interview Guide for 24 1 1
Laypersons.
All participants (PDO Naloxone grantees, ad- Recruitment contact script ............................. 284 1 5/60
visory committee, stakeholders and part-
ners, laypersons).
PDO/Naloxone Grantees ................................ Key Informant Selection Tool ......................... 12 1 15/60
Leroy A. Richardson, DEPARTMENT OF HEALTH AND for a generic clearance to be used for the
Chief, Information Collection Review Office, HUMAN SERVICES financial reports used in the
Office of Scientific Integrity, Office of the administration of mandatory grants.
Associate Director for Science, Office of the Administration for Children and This clearance supports the
Director, Centers for Disease Control and Families Departments initiative of Generating
Prevention. Efficiencies through Streamlined
[FR Doc. 2017–27257 Filed 12–18–17; 8:45 am] Proposed Information Collection
Activity; Comment Request Processes by employing an abbreviated
BILLING CODE 4163–18–P process.
Proposed Projects If approved program offices will be at
Title: ACF Generic Clearance for liberty to tailor a financial report to their
Mandatory Grant Financial Reports. specific needs rather than adhering to a
OMB No.: 0970—New. standard form.
Description: OMB has granted
permission for ACF to submit a request Respondents: States and Territories.
ANNUAL BURDEN ESTIMATES
Number of Average
Number of Total burden
Instrument responses per burden hours
respondents hours
respondent per response
Mandatory Grant Financial Reports ................................................................. 900 4 5 18,000
Estimated Total Annual Burden Families, Office of Planning, Research practical utility; (b) the accuracy of the
Hours: and Evaluation, 330 C Street SW, agency’s estimate of the burden of the
In compliance with the requirements Washington, DC 20201. Attn: ACF proposed collection of information; (c)
of the Paperwork Reduction Act of 1995 Reports Clearance Officer. Email the quality, utility, and clarity of the
(Pub. L. 104–13, 44 U.S.C. Chap. 35), the address: infocollection@acf.hhs.gov. All information to be collected; and (d)
Administration for Children and requests should be identified by the title ways to minimize the burden of the
sradovich on DSK3GMQ082PROD with NOTICES
Families is soliciting public comment of the information collection. collection of information on
on the specific aspects of the The Department specifically requests respondents, including through the use
information collection described above. comments on: (a) Whether the proposed of automated collection techniques or
Copies of the proposed collection of collection of information is necessary other forms of information technology.
information can be obtained and for the proper performance of the Consideration will be given to
comments may be forwarded by writing functions of the agency, including
to the Administration for Children and whether the information shall have
VerDate Sep<11>2014 17:47 Dec 18, 2017 Jkt 244001 PO 00000 Frm 00028 Fmt 4703 Sfmt 4703 E:\FR\FM\19DEN1.SGM 19DEN1](https://thefederalregister.org/doc/82_FR_60442/page/1.svg)
![Federal Register / Vol. 82, No. 242 / Tuesday, December 19, 2017 / Notices 60201
comments and suggestions submitted 10903 New Hampshire Ave., Bldg. 31 • For written/paper comments
within 60 days of this publication. Conference Center, the Great Room (Rm. submitted to the Dockets Management
1503 B+C), Silver Spring, MD 20993– Staff, FDA will post your comment, as
Robert Sargis,
0002. Entrance for the public workshop well as any attachments, except for
Reports Clearance Officer.
participants (non-FDA employees) is information submitted, marked and
[FR Doc. 2017–27306 Filed 12–18–17; 8:45 am] through Building 1, where routine identified, as confidential, if submitted
BILLING CODE 4184–01–P security check procedures will be as detailed in ‘‘Instructions.’’
performed. For parking and security Instructions: All submissions received
information, please refer to https:// must include the Docket No. FDA–
DEPARTMENT OF HEALTH AND www.fda.gov/AboutFDA/ 2017–N–6716 for ‘‘New Insights for
HUMAN SERVICES WorkingatFDA/BuildingsandFacilities/ Product Development and
WhiteOakCampusInformation/ Bioequivalence Assessments of Generic
Food and Drug Administration
ucm241740.htm. Orally Inhaled and Nasal Drug
[Docket No. FDA–2017–N–6716] You may submit comments as Products.’’ Received comments, those
follows. Please note that late, untimely filed in a timely manner (see
New Insights for Product Development filed comments will not be considered. ADDRESSES), will be placed in the docket
and Bioequivalence Assessments of Electronic comments must be submitted and, except for those submitted as
Generic Orally Inhaled and Nasal Drug on or before February 14, 2018. The ‘‘Confidential Submissions,’’ publicly
Products; Public Workshop; Request https://www.regulations.gov electronic viewable at https://www.regulations.gov
for Comments filing system will accept comments or at the Dockets Management Staff
AGENCY: Food and Drug Administration, until midnight Eastern Time at the end between 9 a.m. and 4 p.m., Monday
HHS. of February 14, 2018. Comments through Friday.
received by mail/hand delivery/courier • Confidential Submissions—To
ACTION: Notice of public workshop;
(for written/paper submissions) will be submit a comment with confidential
request for comments.
considered timely if they are information that you do not wish to be
SUMMARY: The Food and Drug postmarked or the delivery service made publicly available, submit your
Administration (FDA, the Agency, or acceptance receipt is on or before that comments only as a written/paper
we) is announcing the following public date. submission. You should submit two
workshop entitled ‘‘New Insights for copies total. One copy will include the
Product Development and Electronic Submissions information you claim to be confidential
Bioequivalence Assessments of Generic Submit electronic comments in the with a heading or cover note that states
Orally Inhaled and Nasal Drug following way: ‘‘THIS DOCUMENT CONTAINS
Products.’’ The purposes of the • Federal eRulemaking Portal: CONFIDENTIAL INFORMATION.’’ The
workshop are to present the outcomes https://www.regulations.gov. Follow the Agency will review this copy, including
from the research projects conducted instructions for submitting comments. the claimed confidential information, in
under the Generic Drug User Fee Comments submitted electronically, its consideration of comments. The
Amendments (GDUFA) Regulatory including attachments, to https:// second copy, which will have the
Science Research Program; discuss how www.regulations.gov will be posted to claimed confidential information
regulatory science initiatives have the docket unchanged. Because your redacted/blacked out, will be available
helped address regulatory science comment will be made public, you are for public viewing and posted on
knowledge gaps by providing insights solely responsible for ensuring that your https://www.regulations.gov. Submit
on factors that influence the comment does not include any both copies to the Dockets Management
performance of generic orally inhaled confidential information that you or a Staff. If you do not wish your name and
and nasal drug products (OINDPs); third party may not wish to be posted, contact information to be made publicly
share the Agency’s experience on the such as medical information, your or available, you can provide this
utility of novel analytical tools and anyone else’s Social Security number, or information on the cover sheet and not
methods developed under the regulatory confidential business information, such in the body of your comments and you
science initiative for generic OINDP as a manufacturing process. Please note must identify this information as
product development and that if you include your name, contact ‘‘confidential.’’ Any information marked
bioequivalence assessments; and obtain information, or other information that as ‘‘confidential’’ will not be disclosed
input from the public on what, when, identifies you in the body of your except in accordance with 21 CFR 10.20
where, and how analytical methods and comments, that information will be and other applicable disclosure law. For
procedures should be applied in the posted on https://www.regulations.gov. more information about FDA’s posting
development and review of abbreviated • If you want to submit a comment of comments to public dockets, see 80
new drug applications (ANDAs) for with confidential information that you FR 56469, September 18, 2015, or access
complex OINDPs. do not wish to be made available to the the information at: https://www.gpo.gov/
public, submit the comment as a fdsys/pkg/FR-2015-09-18/pdf/2015-
DATES: The public workshop will be
written/paper submission and in the 23389.pdf.
held on January 9, 2018, from 8:30 a.m. Docket: For access to the docket to
to 4:30 p.m. Individuals who wish to manner detailed (see ‘‘Written/Paper
Submissions’’ and ‘‘Instructions’’). read background documents or the
attend the workshop must register by electronic and written/paper comments
December 30, 2017. Submit either Written/Paper Submissions received, go to https://
sradovich on DSK3GMQ082PROD with NOTICES
electronic or written comments on this Submit written/paper submissions as www.regulations.gov and insert the
public workshop by February 14, 2018. follows: docket number, found in brackets in the
See the SUPPLEMENTARY INFORMATION • Mail/Hand delivery/Courier (for heading of this document, into the
section for registration date and written/paper submissions): Dockets ‘‘Search’’ box and follow the prompts
information. Management Staff (HFA–305), Food and and/or go to the Dockets Management
ADDRESSES: The public workshop will Drug Administration, 5630 Fishers Staff, 5630 Fishers Lane, Rm. 1061,
be held at FDA White Oak Campus, Lane, Rm. 1061, Rockville, MD 20852. Rockville, MD 20852.
VerDate Sep<11>2014 17:47 Dec 18, 2017 Jkt 244001 PO 00000 Frm 00029 Fmt 4703 Sfmt 4703 E:\FR\FM\19DEN1.SGM 19DEN1](https://thefederalregister.org/doc/82_FR_60442/page/2.svg)
Document Created: 2017-12-19 01:31:35
Document Modified: 2017-12-19 01:31:35
| Category | Regulatory Information | |
| Collection | Federal Register | |
| sudoc Class | AE 2.7: GS 4.107: AE 2.106: | |
| Publisher | Office of the Federal Register, National Archives and Records Administration | |
| Section | Notices | |
| FR Citation | 82 FR 60200 |
2025 Federal Register | Disclaimer | Privacy Policy
USC | CFR | eCFR